Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7907302 | 0.92 | HPGD (0.44) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL7907306 | 0.92 | HPGD (0.44) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL12032390 | 0.91 | HPGD (0.40) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL12032165 | 0.91 | HPGD (0.40) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL7910505 | 0.89 | HPGD (0.42) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL7910499 | 0.89 | HPGD (0.42) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL7910502 | 0.89 | HPGD (0.42) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL12032198 | 0.89 | HPGD (0.37) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL12730609 | 0.88 | HPGD (0.41) | HPGDSMN1; SMN2GLAGAAMAPT | |
| SCHEMBL9406597 | 0.87 | CYP2C9 (0.40) | HPGDSMN1; SMN2GAAMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999197-B2 | Compound having a five-membered ring, the liquid crystal composition and the liquid crystal display device | JNC CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999197-B2 | Compound having a five-membered ring, the liquid crystal composition and the liquid crystal display device | JNC CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140054499-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140054499-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20110309300-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | CHISSO PETROCHEMICAL CORPORATION (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110309300-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | CHISSO PETROCHEMICAL CORPORATION (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110309300-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | CTNND1, HCN1, CTNNA1 | HPGD 4680/4885SMN1; SMN2 4054/4885GLA 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.